Last reviewed · How we verify

AVACINCAPTAD PEGOL SODIUM

FDA-approved approved Quality 24/100

Avacincaptad pegol sodium is an investigational drug with no FDA approval or label. It is being studied for its potential in treating various ophthalmic conditions, particularly those involving the retina. The drug's mechanism of action involves inhibiting complement activation, which is a key component of the immune system that can contribute to inflammation and tissue damage. Despite promising preclinical and early clinical results, the drug is still in development, and its safety and efficacy profiles are not yet fully established. The lack of an FDA label indicates that it has not yet been approved for any specific use, and its commercial prospects remain uncertain.

At a glance

Generic nameAVACINCAPTAD PEGOL SODIUM
Drug classComplement Inhibitors
TargetComplement C5
Therapeutic areaImmunology
PhaseFDA-approved
First approval2023

Approved indications

Pipeline indications

Common side effects

Serious adverse events

Patents

PatentExpiryType
114911762034-07-11Method of Use
112731712034-07-11Method of Use
96175462027-02-14Compound
82367732026-11-11Method of Use
120168752034-07-11Method of Use
75794562027-02-14Compound

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
FDA Orange BookPatents + exclusivity

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: